Premium
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives
Author(s) -
Salem Riad,
Mazzaferro Vincenzo,
Sangro Bruno
Publication year - 2013
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.26382
Subject(s) - hepatocellular carcinoma , medicine , yttrium , radiology , oncology , medical physics , general surgery , chemistry , organic chemistry , oxide
Hepatocellular carcinoma(HCC) is the 6th most common malignancy diagnosed worldwide(1). Late stage presentation, co-morbidities, and limited donor availability enables only 10% of patients to receive curative therapies. Hence, there exists a critical need for novel treatments addressing HCC at all stages. During the last decade, several transarterial locoregional therapies have been developed. One of these, Yttrium-90(Y90) radioembolization, has matured into a recognized treatment option, with a demonstration of a clear palliative role by inducing necrosis and delaying progression(2-8). This overview will describe the biological rationale for Y90, highlight seminal data, propose research questions and discuss the future role of Y90 in HCC.